predominant feature of PMF is BM fibrosis causing extramedullary hematopoiesis, splenomegaly, and anemia. Current treatment options, except for allogeneic stem cell transplantation, are not curative and aim at complication prevention, symptom improvement, and risk minimization of progression to fibrosis or leukemia. 2 The JAK1/2 inhibitor Ruxolitinib (Ruxo) is the first approved drug for the treatment of intermediate/highrisk MF and PV. Although designed as a specific targeted therapy, Ruxo does not cure the disease but has nevertheless demonstrated impressive clinical effectivity including normalization of blood counts, reduction in spleen size, and relief of MPN-related symptoms. 3 Importantly, Ruxo treatment has been reported to prolong survival in MF and to improve or even reverse BM fibrosis after long-term treatment. [4] [5] [6] The effects of Ruxolitinib on blood counts and spleen size can be directly attributed to the drug-induced inhibition of dysregulated JAK-STAT signaling in mutated hematopoietic cells. 7 However, normalization of the inflammatory stromal environment in MPN and improvement of BM might be-at least in part-due to Ruxo effects on other cell types. Of note, Ruxolitinib is effective also in JAK2 non-mutated patients 8 and has been demonstrated to affect dendritic cells, NK cells, and T cells. [9] [10] [11] Whether non-hematopoietic BM stromal cells (MSC), which are not only important elements of the BM stroma and critical regulators of hematopoiesis, 12, 13 but also contribute to the proinflammatory environment 14 and BM fibrosis, 15, 16 
| PATIENTS AND ME THODS

| Healthy and patient bone marrow donors
Bone marrow aspirates were harvested from the iliac crest of consenting healthy donors (n = 10) and patients (n = 7) with myeloproliferative neoplasms (MPNs) and known JAK2 mutational status (see Table 1 ). The study and all related protocols were performed according to the guidelines of the Regional Ethical Review Board in Lund 
| Bone marrow mononuclear cells isolation and MSC culture
Bone marrow mononuclear cells were isolated as described previously 20, 21 by density gradient centrifugation (LSM 1077
Lymphocyte; PAA) after incubation with RosetteSep Human MSC Enrichment Cocktail (Stem Cell Technologies) for lineage depletion (CD3, CD14, CD19, CD38, CD66b, glycophorin A). PharmLyse was used for additional red blood cell removal. Cells were enumerated using a hemocytometer, and they were used either fresh or as third-or fourth-passage MSC after culture in expansion media
Gladbach, Germany) supplemented with 1% antibiotic-antimycotic solution (ThermoFischer Scientific, Sweden).
| Preparation and administration of JAK1/2 inhibitor Ruxolitinib
Ruxolitinib (INCB018424) was purchased from Selleckchem (S1378, Rungsted, Denmark). The compound was dissolved in 100% DMSO and used at the following final concentrations: 
| Clonogenicity assay
Colony formation was evaluated using freshly isolated BM-MNC from 9 different healthy BM donors. CFU-F cultures were performed in 6-well plates as previously described. 20 Briefly, 20 000 MNC/cm 2 Table S1 . Human GAPDH was used as a reference gene, and the relative expression of each mRNA was determined using the relative −ΔΔCt method.
| IL-6 stimulation of healthy donor MSC
Human recombinant IL-6 (Cell Signaling Technology, BioNordika, Stockholm, Sweden) was diluted in sterile phosphate-buffered saline (PBS, Hyclone, GE Healthcare Life Sciences, Uppsala, Sweden) with 5% FBS and added to the cultured MSC at a final concentration of 100 ng/mL. 
| Western blot analysis
| Cytokine assays
The 
| ELISA
Human chemokine CCL2/MCP-1 and IL-6 cytokine levels were assessed in cell culture supernatants of P3 MSC from patients with JAK2 V617F MPNs and age-matched controls using Quantikine ELISA kits (R&D systems, Biotechne, Abingdon, UK) following the manu- 
| Statistical analysis
One-way or two-way analysis of variance (ANOVA) combined with Tukey's multiple comparisons tests for inter-group comparisons was applied using the GraphPad Software, (v7.00, La Jolla California USA, www.graphpad.com). Statistical significance was set at P ≤ .05.
| RE SULTS
| Ruxolitinib only slightly affected healthy donor MSC survival and proliferation
First, the direct effects of Ruxolitinib on proliferation and survival of cultured healthy donor MSC were investigated. As shown in Figure 1A , increasing concentrations of
increased numbers in the lower doses ranges and a tendency to reduced numbers of Ruxolitinib-treated MSC relative to their corresponding DMSO controls at higher dose levels in short-term exposure experiments (6 hours, 12 hours, 24 hours and 48 hours).
However, differences in cell survival rates were not statistically significant. Nevertheless, time was identified as a significant factor for cell survival at 24 hours. In the next step, the long-term toxicity of Ruxolitinib on MSC was assessed ( Figure 1B) . Again, a decrease in cell numbers up to about 50%-60% was observed at the highest concentrations (5 μmol/L and 10 μmol/L, day 14 and 21); however, differences were not statistically significant when compared to corresponding DMSO controls neither with regard to time nor dose.
In comparison, proliferation of JAK2 V617F -positive human erythroleukemia cells (HEL) was significantly affected by Ruxolitinib ( Figure S1 ). As expected and in accordance with previous reports, HEL cell proliferation was inhibited in a dose-dependent fashion by Ruxolitinib (P < .001, one-way ANOVA) ( Figure S1A ), and reduced cell proliferation rates were also apparent during the course of 7 days of Ruxolitinib administration (1 μmol/L) ( Figure S1B ).
Additional cell-cycle analysis experiments further indicated that
Ruxolitinib induced a significant decrease of HEL cells in G 2 phase (data not shown).
| Ruxolitinib did not affect healthy donor MSC clonogenicity
Next, we investigated whether the clonogenic capacity of HD-MSC as measured by the CFU-F (colony-forming unit, fibroblast) assay would be affected by JAK2 inhibitor treatment. In a series of 9 independent experiments with MSC from healthy donors, no statistically significant decreases in CFU-F frequency of Ruxolitinibexposed MSC compared to DMSO-treated controls were observed ( Figure 1C) . Interestingly, however, increased colony numbers were found at 5 μmol/L Ruxolitinib, that is, the second highest dose tested. In accordance with the proliferation data, colony size measurements showed a trend toward smaller colonies with increasing doses of Ruxolitinib ( Figure 1D ), but differences were not statistically significant.
F I G U R E 1 Ruxolitinib effects on in vitro MSC growth and survival.(A, B)
Third passage healthy donor (HD) MSC were subjected to shortterm (A) and long-term (B) exposure with increasing doses of Ruxolitinib. Complete media changes were performed every 48 h. Data are presented as mean (± SD) relative numbers of viable Ruxolitinib-treated MSC compared to their corresponding DMSO controls (fraction of DMSO controls). Differences were not significant (n = 3 for both short-and long-term exposure, two-way ANOVA) but time was identified as a significant factor for cell survival at 24 h (P = .028, two-way ANOVA). (C) HD-MSC were treated with increasing doses of Ruxolitinib and assayed for clonogenic progenitor cells (CFU-F). Data are shown as mean (± SD) relative number of colonies compared to DMSO-treated controls (n = 9) (fraction of DMSO controls). Colony numbers were significantly higher in the 5 μmol/L Ruxolitinib group compared to the no drug/no DMSO control (*P = .04, unpaired t test). Differences observed at the other dose levels were not significant (ordinary one-way ANOVA, P = .431). (D) Evaluation of colony sizes of Ruxolitinib-and control-treated CFU-F showed a tendency to decreased colony diameters in the Ruxolitinib groups. Bars show the mean (± SD) diameters for the Ruxolitinib-and their respective DMSO-treated cells (n = 5, one-way ANOVA, P = .52). (E, F) Third passage patient (P)-MSC were subjected to short-term (E) and long-term exposure (F) with increasing doses of Ruxolitinib. Complete media changes were performed every 48 h. Data are presented as mean (± SD) relative numbers of viable Ruxolitinibtreated MSC compared to their corresponding DMSO controls (fraction of DMSO controls). Differences were significant for dose in short-term exposure experiments (n = 3, two-way ANOVA, P < .0001), but not in the long-term exposure experiments (n = 2, two-way ANOVA) Mutational analysis showed that all tested P-MSC and HD-MSC were negative for the JAK2 V617F mutation (n = 3 per group). In contrast to HD-MSC, patient MSC (P-MSC) were significantly affected by Ruxolitinib in short-term exposure (48 hours) assays at lower doses ( Figure 1E ). Here, the most pronounced effect was recorded for the 0.2 μmol/L dose. Interestingly, at the highest Ruxolitinib concentrations (5 μmol/L and 10 μmol/L), P-MSC numbers were not decreased but rather increased, which was in contrast to HD-MSC across all time-points studied ( Figure 1A and 1E ).
On the other hand, long-term exposure to Ruxolitinib resulted in decreased cell numbers at doses equal to or greater than 0.5 μmol/L after 3 and 7 days of culture ( Figure 1F ). However, cell numbers recovered to control levels by day 14 despite continuous drug exposure.
| Ruxolitinib effects on gene expression and JAK-STAT signaling in healthy donor and patient MSC
Next, potential expression differences of genes reported in the context of BM fibrosis and hematopoietic stem cell (HSC) regulation were investigated in P-MSC compared to HD-MSC (Figure 2A-B) .
Expression levels of fibrosis-related genes lysyl-oxidase 2 (LOXL2), Phosphorylated STAT3 was considerably reduced in both healthy age-matched MSC and patient MSC exposed to 5 μmol/L of Ruxolitinib for 24 hours ( Figure 2C ). In addition, phosphorylated AKT (Ser473) levels were lower in the Ruxolitinib-treated samples ( Figure 2C ).
| JAK2 inhibition modified the secretory profile of normal and patient MSC
Using the cytokine array as a screening method, the profile of selected cytokines and chemokines was assessed in MSC culture supernatants from healthy donors with and without IL-6 stimulation and subsequent Ruxolitinib treatment ( Figure 3A ). IL-6 was used in these experiments for JAK-STAT pathway activation. 22 Detectable protein levels were re- 
| D ISCUSS I ON
Ruxolitinib is the only JAK inhibitor that is established in routine clinical practice for the treatment of PMF and PV. Ruxolitinib induced remarkable clinical responses on spleen size and MPN-related constitutional symptoms and was demonstrated to prolong overall survival 23 and potentially reverse BM fibrosis.
5,6
F I G U R E 2 Ruxolitinib-affected MSC expression of fibrosis-associated and hematopoiesis-maintenance genes and STAT downstream signaling. A, Fold change expression of genes associated with fibrosis and hematopoiesis maintenance in P-MSC(n = 4), relative to HD-MSC (n = 1). Data are expressed as mean ± SD from 2 independent experiments (****P < .0001, one-way ANOVA). B, Ruxolitinib (1 μmol/L, 36 h exposure) effects on the expression of fibrosis-associated and hematopoietic maintenance genes in P-MSC (Patient P-MSC4 and P-MSC5). Mesenchymal stromal cells are not only important elements of the normal hematopoietic microenvironment (HME) but also of the malignant stem cell niche. 14, 24 Moreover, MSC contribute to fibrosis in MF 25 and JAK2, the primary target of Ruxolitinib, is ubiquitously expressed. Thus, the drug is not acting specifically on malignant cells, and it was therefore reasonable to assume that Ruxolitinib would affect also MSC, a question that has not been addressed previously.
The results of the in vitro proliferation experiments showed only moderate direct cytotoxic effects of Ruxolitinib on healthy donor MSC. Interestingly, Ruxolitinib seemed to even promote MSC growth at lower doses ( Figure 1A-B) and CFU-F growth was increased at 5 μmol/L, clearly above the clinically observed plasma peak levels. 22, 26 In comparison, JAK2 V617F -positive HEL cell proliferation was clearly inhibited by Ruxo ( Figure S1 ), with an IC50 that was similar to other JAK mutated cell lines. 8 In vitro erythroid colony formation was also reported to be affected by Ruxo (IC50s of 67 nmol/L and 407 nmol/L for patient and healthy donors, respectively). 8 However,
Ruxo inhibited the growth of CD34 BM cells from JAK2 V617F patients but not normal cord blood controls. P-MSC also showed a higher expression of hematopoiesis and stem cell-related genes CDH2, SDF-1, and ANGPT1, which decreased when exposed to Ruxolitinib ( Figure 2B ). Interestingly, CDH2
(N-cadherin) has been reported to be involved in stroma-mediated resistance to tyrosine-kinase inhibition in chronic myeloid leukemia (CML). 34 Increased levels of CDH2 in MPN patients might therefore also be related to therapy resistance in MPNs and thus may represent a possible target for treatment optimization. In accordance with previous reports, SDF1 levels were higher in patient MSC, which is of interest as SDF1 has been implicated in MPN-related stem cell migration and extramedullary hematopoiesis. 35 Angiopoietin-1 (ANGPT-1) is expressed by BM stromal cells and hematopoietic progenitors and was reported to regulate niche regeneration after injury. 36 ANGPT-1 levels were found to be elevated in AML and CML patients. 37 Our data showed that ANGPT-1 displayed higher expression levels also in MPN stroma and might be affected by Ruxolinitib Medium control: medium only; IL-6 control: medium supplemented with 100 ng/mL IL-6. Chemokine/cytokine concentrations of MCP-1 (P = .0012) (B) and IL-6 levels (P < .0001) (C),TGFb1 (D) and matrix metalloproteinase MMP-2 (E) in cell culture supernatants of HD-MSC and patient MSC (patients P-MSC4-6) after Ruxolitinib (1 μmol/L) exposure for 24 h. Data are presented as mean ± SD in B-C (n = 3 P-MSC, n = 1 HD-MSC, data from 2 independent experiments) and mean ± CV from technical duplicates in D-E (n = 2 P-MSC, n = 3 HD-MSC). Significant differences are indicated as ****P < .0001, **P = .005 (one-way ANOVA with Tukey's multiple comparisons test). MCP-1 and IL-6 levels were measured by ELISA and single-plex assays were used for TGFb1 and MMP-2 quantification 
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